07 September 2020 : Clinical Research
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
Xianghua Zeng123CDEG, Shicong Zhu12BCD, Cheng Xu4CF, Zhongyu Wang12CD, Xingxing Su12CD, Dong Zeng12CD, Haixia Long12AF*, Bo Zhu12AGDOI: 10.12659/MSM.922576
Med Sci Monit 2020; 26:e922576
Table 3 Baseline and comparison of characteristics in patients with NSCLC based on the Charlson comorbidity index and simplified comorbidity score.
| Characteristics | Value | CCI | SCS | ||||
|---|---|---|---|---|---|---|---|
| <1 (n=38) | ≥1 (n=28) | P | <8 (n=41) | ≥8 (n=25) | P | ||
| Age (years) | 58.5±10.8 | 55.9±10.0 | 62.1±10.9 | 0.018 | 56.1±11.1 | 62.5±9.1 | 0.019 |
| Sex | 0.971 | 0.001 | |||||
| Male | 52 (78.8%) | 30 (78.9%) | 22 (78.6%) | 27 (65.9%) | 25 (100%) | ||
| Female | 14 (21.2%) | 8 (21.1%) | 6 (21.4%) | 14 (34.1%) | 0 | ||
| BMI (kg/m) | 22.8±3.6 | 23.0±3.1 | 22.6±4.2 | 0.736 | 22.8±3.2 | 22.8±4.2 | 0.991 |
| TNM stages | 0.241 | 0.878 | |||||
| III | 23 (34.8%) | 11 (28.9%) | 12 (42.9%) | 14 (34.1%) | 9 (36.0%) | ||
| IV | 43 (65.2%) | 27 (71.1%) | 16 (57.1%) | 27 (65.9%) | 16 (64.0%) | ||
| Pathological type | 0.684 | 0.888 | |||||
| Adenocarcinoma | 39 (59.1%) | 23 (60.5%) | 16 (57.1%) | 25 (61.0%) | 14 (56%) | ||
| Squamous cell carcinoma | 24 (36.4%) | 14 (36.8%) | 10 (35.7%) | 14 (34.1%) | 10 (40.0%) | ||
| Other types | 3 (4.5%) | 1 (2.6%) | 2 (7.2%) | 2 (4.9%) | 1 (4.0%) | ||
| ECOG PS | 0.826 | 0.262 | |||||
| 0–1 | 64 (97.0%) | 37 (97.4%) | 27 (96.4%) | 39 (95.1%) | 25 (100%) | ||
| ≥2, n (%) | 2 (3.0%) | 1 (3.6%) | 1 (3.6%) | 2 (4.9%) | 0 | ||
| PD1 inhibitors | 0.049 | 0.900 | |||||
| Nivolumab | 17 (25.8%) | 6 (15.8%) | 11 (39.3%) | 10 (24.4%) | 7 (28.0%) | ||
| Pembrolizumab | 23 (34.8%) | 13 (34.2%) | 10 (35.7%) | 14 (34.1%) | 9 (36.0%) | ||
| Toripalimab | 26 (39.4%) | 19 (50.0%) | 7 (25.0%) | 17 (41.5%) | 69 (36.0%) | ||
| Smoking history | 0.840 | <0.001 | |||||
| Never | 31 (47.0%) | 17 (44.7%) | 14 (50.0%) | 28 (68.3%) | 3 (12.0%) | ||
| Ever | 16 (24.2%) | 12 (31.6%) | 7 (25.0%) | 6 (14.6%) | 13 (52.0%) | ||
| Current | 19 (28.8%) | 9 (23.7%) | 7 (25.0%) | 7 (17.1%) | 9 (36.0%) | ||
| Drinking status | 0.180 | 0.003 | |||||
| Never | 53 (80.3%) | 28 (73.7%) | 25 (89.3%) | 38 (92.7%) | 15 (60.0%) | ||
| Ever | 5 (7.6%) | 7 (18.4%) | 1 (3.6%) | 1 (2.4%) | 7 (28.0%) | ||
| Current | 8 (12.1%) | 3 (7.9%) | 2 (7.1%) | 2 (4.9%) | 3 (12.0%) | ||
| Data are presented as mean±standard deviation or n (%).NSCLC – non-small cell lung cancer; BMI – body mass index; CCI – Charlson comorbidity index; ECOG PS – Eastern Cooperative Oncology Group performance status; PD1 – programmed cell death protein 1; SCS – simplified comorbidity score. | |||||||